Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Market Movers
TipRanks 50 Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
NTLA
Stock Latest News
Company Announcements
Regeneron and Intellia’s Gene Therapy Study for Hemophilia B: A Market Game-Changer?
1d ago
NTLA
REGN
Premium
Company Announcements
Regeneron and Intellia’s Gene Therapy Study: A Potential Game-Changer for Hemophilia B
3d ago
NTLA
REGN
Premium
Weekend Updates
Insider Sales Shake Royal Caribbean, Kroger, HP, Intellia, EOG
14d ago
KR
EOG
Premium
Ratings
Promising Phase 1 Results and High Interest in Phase 3 Trial Boost Buy Rating for Intellia Therapeutics
1M ago
NTLA
Premium
Company Announcements
Intellia Therapeutics Announces Positive Phase 1 Trial Data
1M ago
8K
NTLA
Premium
Ratings
Intellia Therapeutics’ Lonvo-z Shows Promising Efficacy and Safety, Supporting Buy Rating
1M ago
NTLA
Premium
Ratings
Intellia Therapeutics’ NTLA-2002 Shows Promising Efficacy and Safety in HAE Treatment, Supporting Buy Rating
1M ago
NTLA
Premium
Ratings
Intellia’s Lonvo-z: Promising Phase 1 Results Amid Market Competitiveness and Safety Concerns
1M ago
NTLA
Premium
Ratings
Intellia Therapeutics: Expert Confidence in Addressing Liver Enzyme Concerns Supports Buy Rating
1M ago
NTLA
Premium
Company Announcements
Intellia Therapeutics Holds Annual Stockholders’ Meeting
1M ago
8K
NTLA
Premium
The Fly
Intellia Therapeutics price target lowered to $54 from $74 at Canaccord
2M ago
NTLA
Premium
The Fly
Cathie Wood’s ARK Investment buys 226K shares of Intellia Therapeutics today
2M ago
NTLA
Premium
Ratings
Positive Outlook on Intellia Therapeutics Despite Mild Adverse Event in Phase 3 Study
2M ago
NTLA
Premium
Ratings
Intellia Therapeutics: Positive Outlook and Strong Enrollment Support Buy Rating
2M ago
NTLA
Premium
Ratings
Intellia’s Phase 3 Programs Progress Unhindered Despite Safety Concerns
2M ago
NTLA
Premium
The Fly
Cathie Wood’s ARK Investment buys 201K shares of Intellia Therapeutics today
2M ago
NTLA
Premium
The Fly
Court blocks Trump tariffs, Musk steps away from DOGE: Morning Buzz
2M ago
S
AI
Premium
Ratings
Intellia Therapeutics Faces Safety and Efficacy Challenges with Nex-Z: Analyst Issues Sell Rating
2M ago
NTLA
Premium
The Fly
Intellia commercial position in question after safety event. says Goldman
2M ago
NTLA
Premium
The Fly
Intellia Therapeutics price target lowered to $39 from $43 at BofA
2M ago
NTLA
Premium
The Fly
Intellia adverse event could resurface questions, says JPMorgan
2M ago
NTLA
Premium
The Fly
Intellia discloses grade 4 liver transaminase elevation in MAGNITUDE trial
2M ago
NTLA
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >
You need to enable JavaScript to run this app.
